KBC Group
NTLA icon

KBC Group’s Intellia Therapeutics NTLA Stock Holding History

KBC Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66K Hold
3,928
– – ﹤0.01% 1615
2026
Q1 		$50K Sell
3,928
-2,165
-36% -$27.6K ﹤0.01% 1652
2025
Q4 		$55K Hold
6,093
– – ﹤0.01% 1608
2025
Q3 		$105K Hold
6,093
– – ﹤0.01% 1226
2025
Q2 		$57K Hold
6,093
– – ﹤0.01% 1546
2025
Q1 		$43K Hold
6,093
– – ﹤0.01% 1818
2024
Q4 		$71K Buy
6,093
+2,340
+62% +$36.5K ﹤0.01% 1727
2024
Q3 		$77K Buy
3,753
+1,020
+37% +$23.5K ﹤0.01% 1459
2024
Q2 		$61K Buy
2,733
+940
+52% +$22.4K ﹤0.01% 1499
2024
Q1 		$49K Hold
1,793
– – ﹤0.01% 1572
2023
Q4 		$55K Hold
1,793
– – ﹤0.01% 1461
2023
Q3 		$57K Buy
+1,793
New +$69.6K ﹤0.01% 1337
2020
Q4 		– Sell
-1,020
Closed -$20K – 1277
2020
Q3 		$20K Hold
1,020
– – ﹤0.01% 1213
2020
Q2 		$21K Hold
1,020
– – ﹤0.01% 1248
2020
Q1 		$12K Hold
1,020
– – ﹤0.01% 1266
2019
Q4 		$15K Sell
1,020
-2,940
-74% -$40.9K ﹤0.01% 1469
2019
Q3 		$53K Buy
3,960
+3,440
+662% +$54.8K ﹤0.01% 1384
2019
Q2 		$9K Hold
520
– – ﹤0.01% 1438
2019
Q1 		$9K Buy
520
+260
+100% +$3.88K ﹤0.01% 1397
2018
Q4 		$4K Sell
260
-265
-50% -$4.93K ﹤0.01% 1305
2018
Q3 		$14K Hold
525
– – ﹤0.01% 1375
2018
Q2 		$14K Hold
525
– – ﹤0.01% 1274
2018
Q1 		$11K Hold
525
– – ﹤0.01% 1262
2017
Q4 		$10K Buy
+525
New +$12.1K ﹤0.01% 1247

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

KBC Group's NTLA Position: Q2 2026 in Review

KBC Group held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 3,928 shares worth $66K. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

KBC Group first reported a position in NTLA in Q4 2017 and has held it in 24 quarters since. The position peaked at $105K in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • KBC Group held 3,928 shares of Intellia Therapeutics worth $66K as of Q2 2026.
  • KBC Group left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1615 holding.
  • KBC Group first reported a position in Intellia Therapeutics in Q4 2017 and has held it in 24 quarters since.
  • KBC Group's Intellia Therapeutics position peaked at $105K in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.